Erratum: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (Cancer Chemotherapy and Pharmacology (2015) DOI: 10.1007/s00280-014-2609-3)

H. S. Hochster; N. Uboha; W. Messersmith; P. J. Gold; B. H. Oneil; D. Cohen; C. Denlinger; S. Cohen; C. G. Leichman; L. Leichman; H. J. Lenz

doi:10.1007/s00280-014-2625-3

Erratum: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (Cancer Chemotherapy and Pharmacology (2015) DOI: 10.1007/s00280-014-2609-3)

H. S. Hochster
, N. Uboha
, W. Messersmith
, P. J. Gold
, B. H. Oneil
, D. Cohen
, C. Denlinger
, S. Cohen
, C. G. Leichman
, L. Leichman
, H. J. Lenz

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	25
Number of pages	1
Journal	Cancer Chemotherapy and Pharmacology
Volume	75
Issue number	1
DOIs	https://doi.org/10.1007/s00280-014-2625-3
State	Published - 1 Jan 2015
Externally published	Yes

Access to Document

10.1007/s00280-014-2625-3

Cite this

Hochster, H. S., Uboha, N., Messersmith, W., Gold, P. J., Oneil, B. H., Cohen, D., Denlinger, C., Cohen, S., Leichman, C. G., Leichman, L., & Lenz, H. J. (2015). Erratum: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (Cancer Chemotherapy and Pharmacology (2015) DOI: 10.1007/s00280-014-2609-3). Cancer Chemotherapy and Pharmacology, 75(1), 25. https://doi.org/10.1007/s00280-014-2625-3

@article{4fddb319ace4444fb72c179c0f84a230,

title = "Erratum: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (Cancer Chemotherapy and Pharmacology (2015) DOI: 10.1007/s00280-014-2609-3)",

author = "Hochster, \{H. S.\} and N. Uboha and W. Messersmith and Gold, \{P. J.\} and Oneil, \{B. H.\} and D. Cohen and C. Denlinger and S. Cohen and Leichman, \{C. G.\} and L. Leichman and Lenz, \{H. J.\}",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/s00280-014-2625-3",

language = "English",

volume = "75",

pages = "25",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

Hochster, HS, Uboha, N, Messersmith, W, Gold, PJ, Oneil, BH, Cohen, D, Denlinger, C, Cohen, S, Leichman, CG, Leichman, L & Lenz, HJ 2015, 'Erratum: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (Cancer Chemotherapy and Pharmacology (2015) DOI: 10.1007/s00280-014-2609-3)', Cancer Chemotherapy and Pharmacology, vol. 75, no. 1, pp. 25. https://doi.org/10.1007/s00280-014-2625-3

Erratum: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (Cancer Chemotherapy and Pharmacology (2015) DOI: 10.1007/s00280-014-2609-3). / Hochster, H. S.; Uboha, N.; Messersmith, W. et al.
In: Cancer Chemotherapy and Pharmacology, Vol. 75, No. 1, 01.01.2015, p. 25.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (Cancer Chemotherapy and Pharmacology (2015) DOI: 10.1007/s00280-014-2609-3)

AU - Hochster, H. S.

AU - Uboha, N.

AU - Messersmith, W.

AU - Gold, P. J.

AU - Oneil, B. H.

AU - Cohen, D.

AU - Denlinger, C.

AU - Cohen, S.

AU - Leichman, C. G.

AU - Leichman, L.

AU - Lenz, H. J.

PY - 2015/1/1

Y1 - 2015/1/1

UR - https://www.scopus.com/pages/publications/84937977136

U2 - 10.1007/s00280-014-2625-3

DO - 10.1007/s00280-014-2625-3

M3 - Comment/debate

AN - SCOPUS:84937977136

SN - 0344-5704

VL - 75

SP - 25

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -

Hochster HS, Uboha N, Messersmith W, Gold PJ, Oneil BH, Cohen D et al. Erratum: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (Cancer Chemotherapy and Pharmacology (2015) DOI: 10.1007/s00280-014-2609-3). Cancer Chemotherapy and Pharmacology. 2015 Jan 1;75(1):25. doi: 10.1007/s00280-014-2625-3